Cytogen 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Byung-Hee Jeon

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	14.5%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

업데이트 없음

Recent updates

Is Cytogen (KOSDAQ:217330) Weighed On By Its Debt Load?

Mar 23

What You Need To Know About Cytogen, Inc.'s (KOSDAQ:217330) Investor Composition

Jan 25

Is Cytogen (KOSDAQ:217330) Using Too Much Debt?

Dec 03

CEO

Byung-Hee Jeon (65 yo)

no data

테뉴어

Mr. Jeon Byung-Hee serves as CEO and Representative Director at Cytogen, Inc.

Cytogen 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Recent updates

Cytogen, Inc. (KOSDAQ:A217330) agreed to acquire 99.88% stake in Theragen Genomecare Co. Ltd from Theragen Etex Co.,Ltd. (KOSDAQ:A066700) and Daeilgen Bio for KRW 13.2 billion.

Cytogen, Inc. announced that it expects to receive KRW 6.500000445 billion in funding from Theragen Etex Co.,Ltd.

Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors

Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.

New minor risk - Share price stability

Third quarter 2023 earnings released: ₩149 loss per share (vs ₩149 loss in 3Q 2022)

New minor risk - Shareholder dilution

New major risk - Financial position

Cytogen, Inc. announced that it expects to receive KRW 30 billion in funding

Is Cytogen (KOSDAQ:217330) Weighed On By Its Debt Load?

New 90-day high: ₩61,900

What You Need To Know About Cytogen, Inc.'s (KOSDAQ:217330) Investor Composition

New 90-day high: ₩60,300

New 90-day high: ₩42,000

New 90-day high: ₩40,000

Is Cytogen (KOSDAQ:217330) Using Too Much Debt?

New 90-day high: ₩34,550

New 90-day high: ₩34,000

Cytogen, Inc. announced that it expects to receive KRW 10 billion in funding

Cytogen, Inc. has withdrawn its IPO.

New 90-day low - ₩11,000

CEO

테뉴어